海普瑞(09989)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09989 海普瑞

未开盘 10-16 16:08:14

3.960

+0.035

+0.89%

最高4.005	最低3.935	成交量103.65万
今开3.975	昨收3.925	日振幅1.78%
总市值58.09亿	流通市值8.72亿	总股本14.67亿
成交额412.09万	换手率0.47%	流通股本2.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09989","market":"HK","secType":"STK","nameCN":"海普瑞","latestPrice":3.96,"timestamp":1792138094532,"preClose":3.925,"halted":0,"volume":1036500,"delay":0,"changeRate":0.008917197452229336,"floatShares":220094500,"shares":1467000000,"eps":0.2797646615656268,"marketStatus":"未开盘","change":0.035,"latestTime":"10-16 16:08:14","open":3.975,"high":4.005,"low":3.935,"amount":4120852,"amplitude":0.017834,"askPrice":3.985,"askSize":3000,"bidPrice":3.95,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":0.16243263095938787,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":0,"adr":0,"listingDate":1594137600000,"exchange":"SEHK","adjPreClose":3.925,"dividendRate":0.041944,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":0.9633794963252514,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"002399","market":"SZ","secType":"STK","nameCN":"海普瑞","latestPrice":9.33,"timestamp":1792393200000,"preClose":9.32,"halted":0,"volume":2245400,"delay":0,"premium":"-63.86"}},"requestUrl":"/m/hq/s/09989","defaultTab":"news","newsList":[{"id":"2675815594","title":"洪泽君增持海普瑞(09989.HK)48.7万股 每股作价3.97港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675815594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675815594?lang=zh_cn&edition=full","pubTime":"2026-10-16 19:59","pubTimestamp":1792151944,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110491246","title":"海普瑞（09989）将于10月29日召开董事会审议2026年前三季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1110491246","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110491246?lang=zh_cn&edition=full","pubTime":"2026-10-16 16:36","pubTimestamp":1792139777,"startTime":"0","endTime":"0","summary":"深圳市海普瑞药业集团股份有限公司（09989）10月16日发布公告称，公司董事会计划于2026年10月29日（星期四）举行会议，审议并通过集团截至2026年9月30日止九个月的第三季度业绩及其公告事宜。公告同时列出公司现任董事名单，包括执行董事李锂、李坦、单宇、王建一，以及独立非执行董事黄鹏、易铭、浦洪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674872767","title":"洪泽君增持海普瑞(09989.HK)30.65万股 每股作价约3.98港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674872767","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674872767?lang=zh_cn&edition=full","pubTime":"2026-10-12 19:36","pubTimestamp":1791804990,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09989","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673049099","title":"海普瑞（002399）9月30日主力资金净买入151.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673049099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673049099?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:09","pubTimestamp":1791421740,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，海普瑞报收于9.85元，上涨2.5%，换手率0.33%，成交量4.15万手，成交额4078.03万元。近5日资金流向一览见下表：海普瑞融资融券信息显示，融资方面，当日融资买入194.78万元，融资偿还676.35万元，融资净偿还481.57万元。海普瑞主营业务：肝素产业链、生物大分子CDMO和创新药物的投资、开发及商业化,致力于为全球患者带去高质量的安全有效药物和服务,护佑健康。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800003036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","09989","002399","BK1191","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141520435","title":"海普瑞更新2026年9月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1141520435","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141520435?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:37","pubTimestamp":1791189436,"startTime":"0","endTime":"0","summary":"深圳市海普瑞药业集团股份有限公司于2026年10月5日发布的2026年9月股份变动月报显示，截至2026年9月30日，公司股本结构保持稳定，未发生新增发行、回购或库藏股变动。根据公告，海普瑞的法定/注册股本维持不变，分别为H股220,094,500股和A股1,247,201,704股，合计法定/注册股本总额为人民币1,467,296,204元。另据披露，海普瑞当月未有股份期权、权证或可转债等相关发行及行使活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671261838","title":"海普瑞（002399）9月28日主力资金净买入397.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671261838","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671261838?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:09","pubTimestamp":1790644143,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，海普瑞报收于9.66元，上涨0.84%，换手率0.26%，成交量3.23万手，成交额3111.17万元。近5日资金流向一览见下表：海普瑞融资融券信息显示，融资方面，当日融资买入426.65万元，融资偿还351.53万元，融资净买入75.11万元。海普瑞主营业务：肝素产业链、生物大分子CDMO和创新药物的投资、开发及商业化,致力于为全球患者带去高质量的安全有效药物和服务,护佑健康。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900008288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","09989","002399","BK0070","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669488634","title":"洪泽君增持海普瑞(09989.HK)34.25万股 每股作价3.9港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669488634","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669488634?lang=zh_cn&edition=full","pubTime":"2026-09-23 19:13","pubTimestamp":1790162023,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172227498","title":"海普瑞：洪泽君增持，好仓比例升至12.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172227498","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172227498?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:23","pubTimestamp":1790155428,"startTime":"0","endTime":"0","summary":"洪泽君于2026年9月22日在联交所场内以每股均价3.9000港元买入海普瑞（09989）股份34.25万股，涉资约133.57万港元，属场内主动交易，即在二级市场直接买卖股份。洪泽君此次增持前持有海普瑞好仓2639.45万股，占比11.99%；增持后持股量为2673.70万股，好仓比例升至12.14%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669396121","title":"股市必读：海普瑞新发布《深圳市海普瑞药业集团股份有限公司2026年第一次临时股东会法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669396121","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669396121?lang=zh_cn&edition=full","pubTime":"2026-09-23 02:18","pubTimestamp":1790101090,"startTime":"0","endTime":"0","summary":"深圳市海普瑞药业集团股份有限公司2026年第一次临时股东会决议公告深圳市海普瑞药业集团股份有限公司于2026年9月22日召开2026年第一次临时股东会，会议由董事会召集，董事长李锂主持，采取现场与网络投票结合方式召开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK1191","BK0188","002399","09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168075351","title":"海普瑞（09989）2026年首场临时股东大会通过两项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1168075351","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168075351?lang=zh_cn&edition=full","pubTime":"2026-09-22 19:05","pubTimestamp":1790075141,"startTime":"0","endTime":"0","summary":"深圳市海普瑞药业集团股份有限公司9月22日披露，其2026年第一次临时股东大会以现场及网络方式表决通过全部议案。会议于2026年9月22日14时在深圳市南山区南海大道3031号兰赫美特酒店二楼宴会厅举行。截至股东大会当日，公司已发行股份总数为1,467,296,204股，其中A股1,247,201,704股，H股220,094,500股。本次大会股东及受托代表实际出席并参与表决的股份总数为992,838,085股，占公司已发行股份总数的67.66%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631936","title":"海普瑞：上半年核心制剂业务持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631936","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667631936?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:38","pubTimestamp":1789385903,"startTime":"0","endTime":"0","summary":"近日，海普瑞发布2026年半年度报告。报告期内，公司实现营业收入25.8亿元，归属于上市公司股东的净利润2.75亿元。上半年，海普瑞在高端制剂制造领域也取得重要进展。公司坪山预灌封制剂智造项目获得2026国际制药工程协会（ISPE）年度设施奖（FOYA）“创新-新技术”类别奖。制剂业务是海普瑞上半年经营中的突出亮点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873589764.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873589764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","09989","BK0239","BK0188","002399","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141170366","title":"海普瑞8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1141170366","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141170366?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:41","pubTimestamp":1788338500,"startTime":"0","endTime":"0","summary":"深圳市海普瑞药业集团股份有限公司于2026年9月2日发布了截至2026年8月31日的股份变动月报表。报告期内，海普瑞普通股H股法定注册股本数为2.20亿元，A股法定注册股本数为12.47亿元，两类股份的法定注册股本合计为14.67亿元，与上月保持一致。此外，海普瑞于期内未发生股份期权或股权激励计划之授出、行使、失效变动，也无公司股份的其他购回或注销事项。截至2026年8月31日，海普瑞的总股本数量为14.67亿元，与上月相比无变化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180641526","title":"海普瑞(09989)将于9月22日召开2026年首场临时股东大会 审议增购理财及调整银行授信","url":"https://stock-news.laohu8.com/highlight/detail?id=1180641526","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180641526?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:42","pubTimestamp":1788172979,"startTime":"0","endTime":"0","summary":"公司称，此举有助提高闲置资金使用效率，增强收益。股东需在大会召开24小时前将委任代表表格及相关授权文件送达香港卓佳证券登记有限公司；已提交表格的股东仍可亲自出席并投票。本次会议预计用时不足半天，交通及食宿费用自理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662109127","title":"海普瑞（002399）披露召开2026年第一次临时股东会通知，8月28日股价下跌1.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662109127","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662109127?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:40","pubTimestamp":1787928040,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，海普瑞报收于10.45元，较前一交易日下跌1.42%，最新总市值为153.33亿元。该股当日开盘10.51元，最高10.59元，最低10.42元，成交额达5608.99万元，换手率为0.43%。近日，深圳市海普瑞药业集团股份有限公司披露《关于召开2026年第一次临时股东会的通知》。公告显示，公司将于2026年9月22日召开2026年第一次临时股东会，会议由董事会召集，现场会议时间为当日14:00，网络投票时间为同日9:15至15:00。股权登记日为2026年9月15日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800055479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK1191","BK0188","002399","09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662063706","title":"海普瑞(09989.HK)发布中期业绩 股东应占溢利2.75亿元 同比减少36.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662063706","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662063706?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:23","pubTimestamp":1787909012,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09989","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132023496","title":"海普瑞2026年上半年营收25.63亿元，经调整净利润2.75亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132023496","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132023496?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:05","pubTimestamp":1787907910,"startTime":"0","endTime":"0","summary":"海普瑞公告2026年上半年业绩，报告期内营收25.63亿元，同比下降8.2%。经调整净利润2.75亿元，同比减少36.6%。毛利为8.66亿元，同比增长7.1%，毛利率为33.8%，较上年同期提升4.8个百分点。期末现金及银行结余约13.52亿元。财报显示，销售及分销开支约2.53亿元，同比上升约31%；行政开支约2.87亿元，同比下降约3.4%。其中，肝素制剂收入17.86亿元，同比增长1.0%，毛利率提升至39.7%；API业务收入3.29亿元，同比下降25.9%，主要受价格持续低位及行业竞争加剧影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"海普瑞2026年上半年营收25.63亿元，经调整净利润2.75亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141319233","title":"海普瑞拟将理财及现金管理额度上调至35亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141319233","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141319233?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:03","pubTimestamp":1787907804,"startTime":"0","endTime":"0","summary":"深圳市海普瑞药业集团股份有限公司8月29日公告称，公司第七届董事会第二次会议于2026年8月28日审议通过《关于增加使用自有资金购买理财产品及进行现金管理额度的议案》，拟将自有资金购买理财产品及进行现金管理的总额度由不超过25亿元人民币提高至不超过35亿元人民币。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167133998","title":"海普瑞（09989）下调2026年担保总额至75亿元 授信规模维持185.4亿元不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1167133998","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167133998?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:03","pubTimestamp":1787907802,"startTime":"0","endTime":"0","summary":"2026年8月29日，海普瑞公告称，公司董事会审议通过《调整向银行申请授信额度及提供担保的议案》，拟对2026年度已获批的授信及担保额度进行结构性调整。其余子公司授信额度保持不变。调整后整体授信总规模仍为185.40亿元。调整后，2026年度对外担保总额度下调至75亿元，占公司最近一年经审计净资产的62.34%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116588780","title":"海普瑞(09989)拟将理财额度上调至35亿元 同步下调担保上限","url":"https://stock-news.laohu8.com/highlight/detail?id=1116588780","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116588780?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:03","pubTimestamp":1787907790,"startTime":"0","endTime":"0","summary":"2026年8月28日，深圳市海普瑞药业集团股份有限公司发布公告称，公司董事会审议通过两项议案，并拟提交临时股东大会审议：。额度上调：拟将现有不超过25亿元的理财及现金管理额度增至35亿元。有效期限：自股东批准之日起至公司2026年年度股东大会召开之日止。授信总额度：维持不超过1,854,000万元，授信可在公司及全资附属公司间内部调配使用。担保总额度：由1,009,000万元下调至750,000万元。公司计划适时向股东寄发相关通函及会议通知。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153149004","title":"海普瑞（09989）拟于9月22日召开2026年首场临时股东大会 审议增购理财与授信担保等两项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1153149004","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153149004?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:02","pubTimestamp":1787907767,"startTime":"0","endTime":"0","summary":"深圳市海普瑞药业集团股份有限公司8月29日公告称，公司董事会决定于2026年9月22日14:00在深圳市南山区南海大道3031号兰赫美特酒店二楼宴会厅召开2026年第一次临时股东大会，并同步提供深交所系统及互联网投票渠道。股权登记日为2026年9月15日，届时在中国结算深圳分公司登记在册的全部A股普通股股东均有权参会或委托代理人表决。截至公告披露日，海普瑞执行董事包括李锂、李坦、单宇、张平；独立非执行董事为黄鹏、易铭、浦洪。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09989"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0161},{"period":"1month","weight":-0.0377},{"period":"3month","weight":-0.0594},{"period":"6month","weight":-0.1654},{"period":"1year","weight":-0.2382},{"period":"ytd","weight":-0.2104}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"深圳市海普瑞药业集团股份有限公司是一家主要从事肝素产业链、生物大分子合同开发和生产组织（CDMO）和创新药物的投资、开发及商业化的中国公司。该公司运营四个分部。药品制剂分部生产和销售依诺肝素钠注射液等。原料药物分部生产和销售标准肝素活性药物和依诺肝素活性药物等。CDMO分部提供药物的中间体和原料药工艺研发服务，包括工艺研究、优化、分析检测、制剂研究等。其他分部从事其他产品业务，如胰酶、肠衣等。该公司在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.055012},{"month":2,"riseRate":0.5,"avgChangeRate":0.044203},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.066279},{"month":4,"riseRate":0.5,"avgChangeRate":0.026442},{"month":5,"riseRate":0.666667,"avgChangeRate":0.011756},{"month":6,"riseRate":0.333333,"avgChangeRate":0.009474},{"month":7,"riseRate":0.5,"avgChangeRate":0.026975},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.021639},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.053755},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.027407},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.010172},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.022578}],"exchange":"SEHK","name":"海普瑞","nameEN":"HEPALINK"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海普瑞(09989)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海普瑞(09989)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海普瑞,09989,海普瑞股票,海普瑞股票老虎,海普瑞股票老虎国际,海普瑞行情,海普瑞股票行情,海普瑞股价,海普瑞股市,海普瑞股票价格,海普瑞股票交易,海普瑞股票购买,海普瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海普瑞(09989)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海普瑞(09989)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}